URC: CCPF

About CPRIT GCC Center for Comprehensive PK/PD & Formulation (CCPF)

Contact InformationOpen

Collaboration DataOpen

Internal/External interdisciplinary collaboration for FY 2022:

Dr. Cara Gonzales, UT San Antonio, “Pharmacokinetic studies of a novel anticancer agent CIDD150228
Dr. Shiaw-Yin Lin, MD Anderson Cancer Center, “Pharmacokinetics and metabolic evaluations of a novel anticancer agent R14”
Dr. Ming Hu, UH, “PK/PD evaluations of a novel anticancer agent”
Dr. Marc Cox, UT El Paso, “Novel formulation and structural development of agents for the treatment of prostate cancer”
Dr. Jangsoon Lee, MD Anderson Cancer Center, “LC-MS/MS quantification of three anticancer agents in plasma samples”

Preclinical drug development usually takes several years from the identification of a new chemical entity (NCE) to advance to clinical testing. Most of these pharmacokinetics (PK)/pharmacodynamics (PD) and formulation evaluations are required for Investigational New Drug (IND) applications. Two aspects are generally involved for an NCE at this stage: 1) in vitro PK characterizations (physiochemical properties, metabolism, stability, and cellular and gastrointestinal permeability); and 2) in vivo PK and PD evaluations in animal models. In addition, most NCEs are either unstable or unsuitable for conventional routes of drug administration. Thus, developing an optimal dosage formulation is critical for further NCE candidate development.

Gulf Coast Consortia (GCC) Center for Comprehensive PK/PD & Formulation (CCPF), funded by Cancer Prevention & Research Institute of Texas (CPRIT) in 2018 with $5.1M., is a state-of-the-art drug development core facility with experienced faculty from Texas Southern University College of Pharmacy and Health Science (TSU COPHS), University of Houston College of Pharmacy (UHCOP), and the GCC for Quantitative Biomedical Science. Our primary focus is on preclinical drug development to facilitate rapid advancement of novel cancer drug candidates to clinical trials. We are proud to provide critically needed PK/PD and formulation services to streamline drug development of potential anti-cancer drug candidates identified in existing drug discovery cores, individual labs, and small companies throughout Texas.